Mechanisms and interventions in relapsed/refractory extranodal natural killer/T-cell lymphoma.
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin's lymphoma associated with Epstein-Barr virus and typically involves extranodal sites.
APA
Lu Q, You T, et al. (2025). Mechanisms and interventions in relapsed/refractory extranodal natural killer/T-cell lymphoma.. Drug discovery today, 30(12), 104549. https://doi.org/10.1016/j.drudis.2025.104549
MLA
Lu Q, et al.. "Mechanisms and interventions in relapsed/refractory extranodal natural killer/T-cell lymphoma.." Drug discovery today, vol. 30, no. 12, 2025, pp. 104549.
PMID
41265515
Abstract
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin's lymphoma associated with Epstein-Barr virus and typically involves extranodal sites. The traditional CHOP regimen is no longer standard owing to drug resistance, whereas asparaginase-based therapies have become the mainstay of treatment. However, resistance and tumor invasion lead to relapses in 40-50% of patients, with 20% progressing to relapsed/refractory ENKTL, resulting in a median survival of <12 months. Management of ENKTL remains challenging, with an unmet clinical need. However, although the prognosis for relapsed/refractory ENKTL is poor, the development of new treatment strategies is progressing with a better understanding of the disease. This review examines factors contributing to treatment resistance, underlying resistance mechanisms and potential strategies to overcome ENKTL resistance.
MeSH Terms
Humans; Lymphoma, Extranodal NK-T-Cell; Drug Resistance, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Neoplasm Recurrence, Local; Animals
같은 제1저자의 인용 많은 논문 (5)
- Development and Validation of Nomograms to Predict Overall Survival and Cancer-Specific Survival for Non-Small Cell Lung Cancer with Chest Wall Invasion: A Retrospective Study Based on SEER Database.
- Stratified impact analysis of intrinsic phenotypes and therapeutic interventions on the clinical prognosis of cross-disease validation: right treatment for right patient in precision radiotherapy.
- RAD54B as a biomarker for prognosis and immunotherapy response in bladder cancer.
- High-Entropy Alloy Synergized with Gene Editing for Cocktail-Sensitized Radioimmunotherapy of Lung Metastases.
- Investigation of CT imaging-based BiS drug-loaded nanoparticles for the diagnosis and therapy of colorectal cancer.